Mass spectrometry in neonatal medicine and clinical diagnostics - the potential use of mass spectrometry in neonatal brain monitoring

被引:4
|
作者
Spitzer, Alan R. [1 ]
Chace, Donald [1 ]
机构
[1] Pediat Med Grp, Sunrise, FL 33323 USA
关键词
D O I
10.1016/j.clp.2006.06.005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Mass spectrometry (MS) has had an important place in clinical chemistry and laboratory diagnostics for the past 4 decades. Historically, the value of MS was in its ability to measure the mass of bioactive metabolites (eg, amino acids, fatty acids, organic acids, steroids, lipids, neurotransmitters) in a selective, accurate, and comprehensive manner. Its primary use during this period was the organic acid analysis of urine for the diagnosis of metabolic abnormalities, and this capability remains one of its most important applications. Traditionally, most of these MS analyses were conducted in specialty, expert laboratories because the complex profiles produced by such devices required interpretation by experts in intermediary metabolism. In these applications, a mass spectrometer was often used in conjunction with a physical separation device (eg, gas chromatograph) to detect the mass of the intact molecule and its fragments. The fragmentation pattern uniquely identified a particular molecule that, when coupled to a retention time on a chromatographic device, was considered the gold standard in clinical analysis.
引用
收藏
页码:729 / +
页数:17
相关论文
共 50 条
  • [41] Neonatal screening for inborn errors of metabolism using tandem mass spectrometry
    Sander, J
    Janzen, N
    Sander, S
    Melchiors, U
    Steuerwald, U
    MONATSSCHRIFT KINDERHEILKUNDE, 2000, 148 (08) : 771 - 777
  • [42] Mass spectrometry for use in ethylene furnace monitoring and control
    Astle, GC
    9TH ETHYLENE PRODUCERS' CONFERENCE, PROCEEDINGS, 1997, 6 : 325 - 342
  • [43] The clinical potential of prm-PASEF mass spectrometry
    Lesur, Antoine
    Dittmar, Gunnar
    EXPERT REVIEW OF PROTEOMICS, 2021, 18 (02) : 75 - 82
  • [44] Clinical potential of mass spectrometry-based proteogenomics
    Zhang, Bing
    Whiteaker, Jeffrey R.
    Hoofnagle, Andrew N.
    Baird, Geoffrey S.
    Rodland, Karin D.
    Paulovich, Amanda G.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (04) : 256 - 268
  • [45] Clinical potential of mass spectrometry-based proteogenomics
    Bing Zhang
    Jeffrey R. Whiteaker
    Andrew N. Hoofnagle
    Geoffrey S. Baird
    Karin D. Rodland
    Amanda G. Paulovich
    Nature Reviews Clinical Oncology, 2019, 16 : 256 - 268
  • [46] Tandem mass spectrometry - The potential
    Bartlett, K
    Pourfarzam, M
    JOURNAL OF INHERITED METABOLIC DISEASE, 1999, 22 (04) : 568 - 571
  • [47] Clinical and Gene Analysis of Fatty Acid Oxidation Disorders Found in Neonatal Tandem Mass Spectrometry Screening
    Wang, Xiaoxia
    Fang, Haining
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2023, 16 : 577 - 587
  • [48] Enhancing precision medicine through clinical mass spectrometry platform
    Hristova, Julieta
    Svinarov, Dobrin
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2022, 36 (01) : 106 - 116
  • [49] Clinical Mass Spectrometry-Achieving Prominence in Laboratory Medicine
    Annesley, Thomas M.
    Cooks, Graham
    Herold, David A.
    Hoofnagle, Andrew N.
    CLINICAL CHEMISTRY, 2016, 62 (01) : 1 - 3
  • [50] Conjugating immunoassays to mass spectrometry: Solutions to contemporary challenges in clinical diagnostics
    Stevens, Katherine G.
    Pukala, Tara L.
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2020, 132